Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated July 1, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing specifically details transactions executed under a sub-programme initiated on May 6, 2024, within a broader 12-month repurchase plan starting February 6, 2024.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 20 billion over 12 months (starting Feb 6, 2024).
- Sub-programme Cap (May 6 - Aug 5, 2024): Up to DKK 2.2 billion.
- Accumulated Repurchases (as of June 28, 2024): 10,061,625 B shares purchased since Feb 6, 2024.
- Total Transaction Value (since Feb 6, 2024): DKK 8,788,370,170.
- Average Purchase Price (since Feb 6, 2024): DKK 873.45 per B share.
- Treasury Shares Held: 11,427,189 B shares (0.3% of total share capital).
Material Changes and Recent Activity
Between June 24, 2024, and June 28, 2024, the company executed five transactions under the May 6 sub-programme:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| June 24, 2024 | 36,500 | 987.93 | 36,059,590 |
| June 25, 2024 | 29,835 | 1,009.16 | 30,108,239 |
| June 26, 2024 | 39,000 | 1,016.16 | 39,630,404 |
| June 27, 2024 | 36,000 | 1,003.37 | 36,121,439 |
| June 28, 2024 | 36,000 | 1,006.92 | 36,249,003 |
Accumulated purchases under the specific May 6 programme reached 1,327,375 shares with a total value of DKK 1,260,635,397 as of June 28, 2024.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. The company operates under the "Safe Harbour Rules" of the EU Market Abuse Regulation.
Risks and Contingencies: The filing does not disclose specific operational risks or contingencies beyond the standard regulatory framework for share buybacks. The filing text does not provide a clear value for revenue, profit, cash flow, margins, or debt levels.
Key Facts for Investor Verification
- Verify the remaining capacity under the DKK 20 billion total programme (approx. DKK 11.2 billion remaining as of June 28, 2024).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 873.45.
- Monitor the timeline for the conclusion of the 12-month repurchase period (February 2025).
- Check the company's website (novonordisk.com) for daily transaction details as required by the filing.